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EEG as Successful Diagnostic Tool for
Immune Effector Cell-Associated Neurotoxicity Syndrome
Daniel

Introduction
CAR T-cell therapy was first proven effective in 20131 for the
treatment of certain cancers. However, its widespread adoption
is still hindered by side-effects like immune effector cellassociated neurotoxicity syndrome (ICANS). Current research
aims to better predict, diagnose, and treat ICANS so that CAR Tcell therapy can be more widely applied. Although prior studies
have attempted to identify an objective biomarker of ICANS2,
current practice relies on clinical assessment to diagnose ICANS.
We hypothesize that qualitative features of the EEG may be
utilized to develop a physiological grading system of the
severity of ICANS.

Figure 1 - An example EEG from a patient who recently received CAR T
therapy showing a clear patter of generalized periodic discharges (GPDs)
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Results
VE-ICANS Severity Grading Scale
EEG Feature
Delta frequency 1 Hz or less
Delta frequency 1-2 Hz
Delta frequency 2-3 Hz
Delta frequency 3-4 Hz
Moderately low voltage ( <20 μV)
GRDA (Gen. rhythmic delta activity)
GPDs (Gen. Period Discharges)
Theta frequency 4-5 Hz
Theta frequency 5-8 Hz
Alpha frequency > 9
PDR present
NCSE (Nonconvulsive Status Epilepticus)
Low voltage: Extreme / ECS
(Electrocerebral Silence)
Burst suppression
Unreactive EEG

Score
+10
+6
+5
+3
+2
+2
+2
+2
+1
-1
-1
Worst ICANS
Severity

Figure 2 – The
model coefficients
for each feature. A
patient's score is
the sum of all
features present in
their EEG
Visual EEG-based
ICANS (VE-ICANS)
Visual because the
features used were
graded visually by a
person (versus a
quantitative
computer-based
approach)

VE-ICANS correlates with ICANS

We gathered data retrospectively on 137 patients at two
institutions from 2016-2000 who underwent CAR T-cell therapy
with clinical EEGs and developed ICANS.

•
•
•

The features found in the EEG images were the inputs and the
ICANS scores were outputs
We ran a “Learning to Rank” algorithm that compared each
possible pair of inputs.
Logistic Regression was used find the best severity
coefficients for each feature
Performance was measured using the Pearson correlation
coefficient between original ICANS scores and new calculated
score.

Discussion
➢ This study is the first to describe the full range of
electrophysiological changes observed in ICANS, including features
of prior indeterminate clinical significance.
➢ We developed a qualitative grading scale with a physiological basis
that has a strong correlation to ICANS (R = 0.58). This scale shows
promise as an objective diagnostic tool for ICANS.

➢ The retrospective scoring of ICANS may have compromised the
accuracy of the gold standard used to train the model. Also, we
were forced to exclude some images as we could not ensure
patients were not asleep during the EEG.

We assigned ICANS scores for each day according to current
ASTCT standards based on chart documentation of neurological
exam.

•

Figure 4 EEG frequency (Hz) vs. VE-ICANS.
“Slowing” is defined as an EEG frequency less than 8 Hz.

➢ The type and degree of slowing were found to be the most
important features in ICANS severity. They were more important
than some features previously described in ICANS such as GPDs or
seizures which may be observed more rarely and only in the most
severe forms of ICANS.

Data Collection

Analysis: Machine Learning Model
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EEG “slowing” has greatest predictive value

Methods

We generated one 15-second EEG image per patient per day. A
board-certified epileptologist evaluated the images for
qualitative features (Figure 2).
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Figure 3 – Boxplots of predicted scores (VE-ICANS) vs. ICANS scores. Red line indicates
median value.
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Key Terms
CAR-T Cell Therapy - A type of treatment in which a patient's T cells (a type of immune cell)
are changed in the laboratory so that the immune system will attack the cancer cells.
ICANS – A syndrome observed after CAR-T cell therapy, in which patients exhibit confusion
and other neurological symptoms.
EEG – Electroencephalography, an electrophysiological monitoring method to record
electrical activity on the scalp.
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